Payment overview · 2025
General Payments
$441.09
16 reported records · 8 companies
Healthcare provider profile · identity verified
Edwin H Choi, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1245273820
Verified facts
What the public records show
CMS Open Payments records show Edwin H Choi, MD received $441.09 in general payments during 2025 across 16 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Kerendia, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Prolia by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 354 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.88 | 19.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.41 | 18.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.17 | 17.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.45 | 14.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.39 | 10.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.05 | 7.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $29.10 | 6.6% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $25.64 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $441.09 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.88 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $60.34 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $49.58 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.58 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 271 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 354 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 136 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
271 | 57 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
125 | 23 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
33 | 21 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
354 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
354 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
116 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 941 | 219 |
| Amlodipine Besylate | Amlodipine Besylate | 548 | 130 |
| Losartan Potassium | Losartan Potassium | 445 | 105 |
| Vascepa | Icosapent Ethyl | 359 | 65 |
| Jardiance | Empagliflozin | 354 | 64 |
| Celecoxib | Celecoxib | 333 | 72 |
| Omeprazole | Omeprazole | 305 | 58 |
| Creon | Lipase/Protease/Amylase | 271 | 57 |
| Metformin Hcl | Metformin Hcl | 271 | 62 |
| Lidocaine | Lidocaine | 265 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 51 |
| Gabapentin | Gabapentin | 250 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 39 |
| Furosemide | Furosemide | 207 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 177 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 173 | 52 |
| Donepezil Hcl | Donepezil Hcl | 169 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 169 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 34 |
| Farxiga | Dapagliflozin Propanediol | 142 | 23 |
| Kerendia | Finerenone | 136 | 27 |
| Finasteride | Finasteride | 128 | 27 |
| Eliquis | Apixaban | 126 | 18 |
| Linzess | Linaclotide | 125 | 23 |
| Tradjenta | Linagliptin | 123 | 22 |
| Trulicity | Dulaglutide | 116 | 23 |
| Memantine Hcl | Memantine Hcl | 111 | 23 |
| Myrbetriq | Mirabegron | 111 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 109 | 109 |
| Sertraline Hcl | Sertraline Hcl | 109 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 107 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 24 |
| Lisinopril | Lisinopril | 94 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 92 | 30 |
| Potassium Chloride | Potassium Chloride | 84 | 13 |
| Meloxicam | Meloxicam | 82 | 20 |
| Zenpep | Lipase/Protease/Amylase | 82 | 19 |
| Memantine Hcl Er | Memantine Hcl | 81 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 25 |
| Ozempic | Semaglutide | 76 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 12 |
| Carvedilol | Carvedilol | 73 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 19 |
| Trazodone Hcl | Trazodone Hcl | 70 | 15 |
| Famotidine | Famotidine | 67 | 14 |
| Restasis | Cyclosporine | 65 | 13 |
| Alendronate Sodium | Alendronate Sodium | 63 | 17 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | suppressed |
| Glipizide Er | Glipizide | 57 | 11 |
| Risperidone | Risperidone | 57 | 12 |
| Atenolol | Atenolol | 55 | 15 |
| Ibuprofen | Ibuprofen | 54 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 13 |
| Simvastatin | Simvastatin | 48 | 15 |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Glipizide | Glipizide | 47 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 39 |
| Baclofen | Baclofen | 45 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 11 |
| Ketoconazole | Ketoconazole | 43 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 11 |
| Metformin Hcl Er | Metformin Hcl | 41 | 13 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 11 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 29 |
| Diclofenac Epolamine | Diclofenac Epolamine | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 16 |
| Prolia | Denosumab | 33 | 21 |
| Valsartan | Valsartan | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 24 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Cyclosporine | Cyclosporine | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Tadalafil | Tadalafil | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 12 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 14 |
| Temazepam | Temazepam | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Flector | Diclofenac Epolamine | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Permethrin | Permethrin | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $441.09 · 16 records | Bayer Healthcare Pharmaceuticals Inc. | COLLAGENASE SANTYL, CREON, JARDIANCE, Kerendia, LINZESS, MOUNJARO, ORTHOVISC, OTEZLA, QULIPTA, REPATHA, REXULTI, TEPEZZA, UBRELVY, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error